ICP-248
- Generic Name
- ICP-248
ICP-248 in Combination with Azacitidine in Treatment-Naïve Subjects with Acute Myelogenous Leukemia(AML) or Previously Treated Relapsed/Refractory Subjects with Acute Myelogenous Leukemia(R/R AML).
- First Posted Date
- 2024-10-24
- Last Posted Date
- 2025-03-27
- Lead Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
- Target Recruit Count
- 102
- Registration Number
- NCT06656494
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
🇨🇳The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
ICP-248 in Combination with Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- First Posted Date
- 2024-04-22
- Last Posted Date
- 2025-01-20
- Lead Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
- Target Recruit Count
- 226
- Registration Number
- NCT06378138
- Locations
- 🇨🇳
The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
🇨🇳Anhui Provincial Hospital (The First Affiliated Hospital of University of Science and Technology of China), Hefei, Anhui, China
🇨🇳Gansu Provincial People's Hospital, Lanzhou, Gansu, China
Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ICP-248 in Mature B-cell Malignancies
- First Posted Date
- 2024-04-08
- Last Posted Date
- 2024-04-08
- Lead Sponsor
- InnoCare Pharma Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT06351527
The Study of ICP-248 in Patients with Mature B-cell Malignancies
- Conditions
- Hematological Malignancies
- Interventions
- Drug: ICP-248+Orelabrutinib
- First Posted Date
- 2023-02-15
- Last Posted Date
- 2025-02-06
- Lead Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
- Target Recruit Count
- 191
- Registration Number
- NCT05728658
- Locations
- 🇨🇳
The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
🇨🇳The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳Peking University Third Hospital, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.